Three phase III clinical trials have demonstrated the effectiveness of Glyxambi as a treatment to control glycemia in patients with type 2 diabetes. Specifically, it is intended for those chronic patients, over 18 years of age, in which metformin and/or a sulfonylureaThey have not achieved adequate glycemic control, or when they are already being treated with the combination separately of packaging and linagliptin.
The great advantage of this new drug, which is born from the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance is that it combines in a single compressed wallpaper and linagliptin, the family of drugs for the treatment of type 2 diabetes, thus facilitating thetreatment to patients and improving their adhesion.
As Francisco José Tinahones, Head of the Service of the Endocrinology and Nutrition Service of the Virgen de la Victoria de Málaga, “the bad control of type 2 diabetes is associated with microvascular disease, being poorly controlled diabetes, one of the most important causes, one of the most important causes, one of the most important causes, one of the most important causes one of the most important causes one of the most important causesof blindness and renal failure, and an increase in macrovascular disease, which is manifested as myocardial stroke and infarcts, which are one of the main causes of death in developed countries. ”That is why this type of drugs are of special relevance.
Likewise, the expert contributes that Glyxambi is another advance, and that "makes hypoglycemia, a very undesirable effect on classic treatments: sulfonylureas and insulin."
a good security profile
Beyond the efficiency, in terms of the security profile of this drug, the expert added that these drugs separately, "are very safe drugs, in which the side effects are very scarce."In this sense, "Pagliflozine and linagliptin together have clearly demonstrated to be more effective in reducing blood glucose than administered separately and also taken in a single tablet do not increase the side effects described for each of them individually."
Giving more details Francisco José Tinahones recalls that “Linagliptin has a very broad security profile, with few important undesirable effects, and there is also the possibility of using it in patients with DM2 with renal failure;While Employment has demonstrated a reduction in cardiovascular mortality and hospitalization due to heart failure in patients with DM2 with established cardiovascular disease, "also Pagliflozine" has shown in patients with DM2 delay the progression of renal insufficiency to more advanced stages. "
